Kintsugi Selected for Microsoft Pegasus Program, Advancing Innovation in Healthcare AI

Berkeley, CA, February 24, 2025 – Kintsugi, a leader in voice biomarker AI for mental health, is pleased to announce its selection for Microsoft’s Pegasus program, a highly selective initiative designed to accelerate the growth of high-impact startups. Among 80,000 startups in Microsoft’s global ecosystem, Kintsugi is one of just a few companies selected for the healthcare track, a recognition of its innovation and potential to reshape mental healthcare delivery.

‍

The Pegasus program is designed to support startups that demonstrate strong product-market fit and readiness to scale enterprise solutions. Through this partnership, Kintsugi will collaborate with Microsoft’s healthcare ecosystem to enhance its voice biomarker platform and expand its reach. The collaboration aligns with Kintsugi’s mission to make mental health assessments more accessible, precise, and scalable, empowering clinicians with tools to deliver timely and effective care.

‍

“Being part of Microsoft’s Pegasus program reflects our shared commitment to addressing critical gaps in mental health care,” said Grace Chang, Founder and CEO of Kintsugi. “This partnership will help us refine our platform, deepen its integration with healthcare workflows, and extend its impact on patient care. We’re excited to work closely with Microsoft’s teams to bring our solutions to a broader audience and improve outcomes for millions of patients worldwide.”

‍

According to Dr. Prentice Tom, Chief Medical Officer at Kintsugi, “Joining the Microsoft Pegasus Program and having access to a dedicated cloud solutions architect will accelerate the adoption of Kintsugi's mental health screening tool into health systems. This will not only enhance clinicians' ability to identify and address mental health issues in real-time but also improve patient outcomes by providing timely and personalized care. Ultimately, this partnership will drive better mental health support for patients, streamline clinical workflows, and foster a more holistic approach to healthcare.”

‍

Kintsugi’s voice biomarker platform enables the detection of clinical depression and anxiety by analyzing brief speech samples, providing actionable insights that integrate seamlessly into telehealth platforms, clinical call centers, and remote monitoring systems. Its compatibility with existing healthcare workflows ensures a streamlined approach to mental health triage and treatment which addresses the rising global demand for mental health services.

‍

By joining the Pegasus program, Kintsugi gains access to Microsoft’s technical resources, co-selling support, and cloud infrastructure, enabling the company to scale its enterprise solutions while maintaining a focus on responsible AI. This partnership reinforces the importance of leveraging innovation to address critical challenges in healthcare delivery.

‍

As part of the program, Kintsugi plans to optimize its platform for large-scale healthcare applications, drawing on Microsoft’s advanced AI and cloud capabilities. The collaboration underscores a shared vision of creating impactful, scalable solutions that improve care accessibility and outcomes globally.

‍

For more information about Kintsugi and its participation in Microsoft’s Pegasus program, please contact press@kintsugihealth.com or visit www.kintsugihealth.com.

‍

About Kintsugi

Kintsugi is a leader in voice biomarker AI, enabling early detection of clinical depression and anxiety from just 20 seconds of speech. Its API platform integrates seamlessly into call centers, telehealth visits, and remote patient monitoring applications, empowering clinicians to deliver timely, evidence-based mental health care while improving outcomes for patients. Headquartered in Berkeley, California, Kintsugi is dedicated to making mental health care more accessible and effective for individuals worldwide.

‍

‍

‍